Europe — EMA
Nintedanib Ratiopharm
GNH USA supplies Nintedanib Ratiopharm (Nintedanib), a tyrosine kinase inhibitor for pulmonary fibrosis, sclerosis‑ILD and NSCLC therapy. Request a quote.
Request sourcing
What is Nintedanib?
Nintedanib, the active ingredient in Nintedanib Ratiopharm, is a tyrosine kinase inhibitor presented as a capsule for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and is used in combination therapy for non‑small cell lung cancer in appropriate patients.
GNH USA supplies Nintedanib Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, oncology centres and clinics worldwide.
What is Nintedanib used for?
Nintedanib is indicated for fibrotic lung disorders and as part of combination therapy for certain lung cancers. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves pulmonary function and delays worsening. - Non‑small cell lung cancer (in combination therapy): enhances overall treatment efficacy when used with chemotherapy.
What are the side effects of Nintedanib?
Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.
Common Side Effects: - Nausea - Diarrhea - Vomiting - Decreased appetite
Serious or Rare Side Effects: - Hepatic failure - Arterial thromboembolic events - Severe bleeding
What precautions apply to Nintedanib?
Before initiating therapy, clinicians should consider several safety aspects. - Pregnancy: contraindicated (Category D); avoid use during pregnancy. - Liver function: monitor hepatic enzymes regularly during therapy. - Bleeding risk: assess for bleeding disorders and use caution with anticoagulants. - Cardiovascular: evaluate for history of arterial thromboembolic events before starting. - Drug interactions: review concomitant medications for CYP3A4 substrates or inhibitors. - Store at ambient temperature: keep in original container, protect from moisture and heat.
What does Nintedanib interact with?
Nintedanib can interact with several drug classes; careful review is required.
Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Nintedanib exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increased bleeding risk.
Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise levels. - P‑gp inhibitors (e.g., verapamil): may increase exposure. - Diuretics: monitor renal function and electrolytes.
